The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1
- PMID: 33053563
- DOI: 10.1038/s41586-020-2862-z
The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1
Abstract
Pathological degeneration of axons disrupts neural circuits and represents one of the hallmarks of neurodegeneration1-4. Sterile alpha and Toll/interleukin-1 receptor motif-containing protein 1 (SARM1) is a central regulator of this neurodegenerative process5-8, and its Toll/interleukin-1 receptor (TIR) domain exerts its pro-neurodegenerative action through NADase activity9,10. However, the mechanisms by which the activation of SARM1 is stringently controlled are unclear. Here we report the cryo-electron microscopy structures of full-length SARM1 proteins. We show that NAD+ is an unexpected ligand of the armadillo/heat repeat motifs (ARM) domain of SARM1. This binding of NAD+ to the ARM domain facilitated the inhibition of the TIR-domain NADase through the domain interface. Disruption of the NAD+-binding site or the ARM-TIR interaction caused constitutive activation of SARM1 and thereby led to axonal degeneration. These findings suggest that NAD+ mediates self-inhibition of this central pro-neurodegenerative protein.
Similar articles
-
Multiple domain interfaces mediate SARM1 autoinhibition.Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):e2023151118. doi: 10.1073/pnas.2023151118. Proc Natl Acad Sci U S A. 2021. PMID: 33468661 Free PMC article.
-
SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6271-E6280. doi: 10.1073/pnas.1601506113. Epub 2016 Sep 26. Proc Natl Acad Sci U S A. 2016. PMID: 27671644 Free PMC article.
-
The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.Neuron. 2017 Mar 22;93(6):1334-1343.e5. doi: 10.1016/j.neuron.2017.02.022. Neuron. 2017. PMID: 28334607 Free PMC article.
-
Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.Cell Chem Biol. 2020 Jan 16;27(1):1-13. doi: 10.1016/j.chembiol.2019.11.002. Epub 2019 Nov 21. Cell Chem Biol. 2020. PMID: 31761689 Free PMC article. Review.
-
The curious case of SARM1: Dr. Jekyll and Mr. Hyde in cell death and immunity?FEBS J. 2023 Jan;290(2):340-358. doi: 10.1111/febs.16256. Epub 2021 Nov 12. FEBS J. 2023. PMID: 34710262 Review.
Cited by
-
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.Neurotherapeutics. 2022 Jul;19(4):1133-1144. doi: 10.1007/s13311-022-01297-6. Epub 2022 Oct 7. Neurotherapeutics. 2022. PMID: 36207571 Free PMC article. Review.
-
Microglial cGAS-STING signaling underlies glaucoma pathogenesis.Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2409493121. doi: 10.1073/pnas.2409493121. Epub 2024 Aug 27. Proc Natl Acad Sci U S A. 2024. PMID: 39190350
-
SARM1 can be a potential therapeutic target for spinal cord injury.Cell Mol Life Sci. 2022 Feb 28;79(3):161. doi: 10.1007/s00018-022-04195-4. Cell Mol Life Sci. 2022. PMID: 35224705 Free PMC article. Review.
-
Detergents and alternatives in cryo-EM studies of membrane proteins.Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1049-1056. doi: 10.3724/abbs.2022088. Acta Biochim Biophys Sin (Shanghai). 2022. PMID: 35866608 Free PMC article. Review.
-
Targeting Diet and Exercise for Neuroprotection and Neurorecovery in Glaucoma.Cells. 2021 Feb 1;10(2):295. doi: 10.3390/cells10020295. Cells. 2021. PMID: 33535578 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
